Country
Full text data for US,EP,CN
Type
Legal Validity
Legal Status
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC(Section)
IPC(Class)
IPC(Subclass)
IPC(Group)
IPC(Subgroup)
LOC
Agent
Agency
Claims Number
Figures Number
Citation Number of Times
Assignee Number
No. Publication Number Title Publication/Patent Number Publication/Patent Number Publication Date Publication Date
Application Number Application Number Filing Date Filing Date
Inventor Inventor Assignee Assignee IPC IPC
1
EP3865150A1
COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
Publication/Patent Number: EP3865150A1 Publication Date: 2021-08-18 Application Number: 21154546.2 Filing Date: 2016-09-23 Inventor: Lyday, Bruce W   Chen, Tony   Assignee: Primevax Immuno-Oncology, Inc.   IPC: A61K39/00 Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with primed dendritic cells recognizing a tumor antigen. The methods may comprise storing, shipping and/or culturing dendritic cells, where the dendritic cells are stored on a hard surface. Lysis protocols are described where the lysis does not result in complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.
2
US2021236568A1
COMPOSITIONS AND METHODS FOR THERAPY WITH DENGUE VIRUS
Publication/Patent Number: US2021236568A1 Publication Date: 2021-08-05 Application Number: 17/130,349 Filing Date: 2020-12-22 Inventor: Lyday bruce w   Assignee: PrimeVax Immuno-Oncology, Inc.   IPC: A61K35/76 Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with a Dengue Virus and, optionally, primed dendritic cells recognizing a tumor antigen. Lysis protocols are described where the lysis does not result in complete or less than complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.
3
US2021187086A1
COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
Publication/Patent Number: US2021187086A1 Publication Date: 2021-06-24 Application Number: 17/165,270 Filing Date: 2021-02-02 Inventor: Lyday bruce w   Assignee: PrimeVax Immuno-Oncology, Inc.   IPC: A61K39/00 Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
4
US10946080B2
Compositions and methods for combination therapy with dengue virus and dendritic cells
Publication/Patent Number: US10946080B2 Publication Date: 2021-03-16 Application Number: 16/389,445 Filing Date: 2019-04-19 Inventor: Lyday bruce w   Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.   IPC: A61K35/76 Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
5
US10675304B2
Combination immunotherapies for treatment of cancer
Publication/Patent Number: US10675304B2 Publication Date: 2020-06-09 Application Number: 16/413,444 Filing Date: 2019-05-15 Inventor: Lyday bruce w   Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.   IPC: A61K35/15 Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with an immune checkpoint modulatory agent and a strain of an Arbovirus or a strain of an Alphavirus. Also provided herein are also methods for combination therapy comprising administration of an immune checkpoint modulatory agent, tumor antigen primed dendritic cells and an Alphavirus or an Arbovirus.
6
US2020078424A1
COMPOSITIONS AND METHODS FOR THERAPY WITH DENGUE VIRUS
Publication/Patent Number: US2020078424A1 Publication Date: 2020-03-12 Application Number: 16/460,629 Filing Date: 2019-07-02 Inventor: Lyday bruce w   Assignee: PrimeVax Immuno-Oncology, Inc.   IPC: A61K35/76 Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with a Dengue Virus and, optionally, primed dendritic cells recognizing a tumor antigen. Lysis protocols are described where the lysis does not result in complete or less than complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.
7
US2020276235A1
COMBINATION IMMUNOTHERAPIES FOR TREATMENT OF CANCER
Publication/Patent Number: US2020276235A1 Publication Date: 2020-09-03 Application Number: 15/931,787 Filing Date: 2020-05-14 Inventor: Lyday bruce w   Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.   IPC: A61K35/15 Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with an immune checkpoint modulatory agent and a strain of an Arbovirus or a strain of an Alphavirus. Also provided herein are also methods for combination therapy comprising administration of an immune checkpoint modulatory agent, tumor antigen primed dendritic cells and an Alphavirus or an Arbovirus.
8
EP3638303A1
COMPOSITIONS AND METHODS FOR CANCER THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
Publication/Patent Number: EP3638303A1 Publication Date: 2020-04-22 Application Number: 18817312.4 Filing Date: 2018-06-14 Inventor: Lyday bruce w   Chen, Tony   Assignee: Primevax Immuno-Oncology, Inc.   IPC: A61K39/12
9
AU2018285525A1
Compositions and methods for cancer therapy with dengue virus and dendritic cells
Publication/Patent Number: AU2018285525A1 Publication Date: 2020-01-30 Application Number: 2018285525 Filing Date: 2018-06-14 Inventor: Chen, Tony   Lyday bruce w   Assignee: PrimeVax Immuno-Oncology Inc.   IPC: A61P35/00
10
US2020121745A1
COMPOSITIONS AND METHODS FOR CANCER THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
Publication/Patent Number: US2020121745A1 Publication Date: 2020-04-23 Application Number: 16/714,370 Filing Date: 2019-12-13 Inventor: Lyday bruce w   Chen, Tony   Assignee: PrimeVax Immuno-Oncology, Inc.   IPC: A61K35/76 Abstract: Described herein are compositions and methods for treating a disease, particularly a melanoma, with a Dengue Virus and, optionally, primed dendritic cells recognizing a tumor antigen. Lysis protocols are described where the lysis does not result in complete or less than complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.
11
US2020360497A1
COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELLS
Publication/Patent Number: US2020360497A1 Publication Date: 2020-11-19 Application Number: 16/942,058 Filing Date: 2020-07-29 Inventor: Lyday bruce w   Chen, Tony   Assignee: PrimeVax Immuno-Oncology, Inc.   IPC: A61K39/00 Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with primed dendritic cells recognizing a tumor antigen. The methods may comprise storing, shipping and/or culturing dendritic cells, where the dendritic cells are stored on a hard surface. Lysis protocols are described where the lysis does not result in complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.
12
US10765727B2
Compositions and methods for producing dendritic cells
Publication/Patent Number: US10765727B2 Publication Date: 2020-09-08 Application Number: 15/275,073 Filing Date: 2016-09-23 Inventor: Lyday bruce w   Chen, Tony   Assignee: Primevax Immuno-Oncology, Inc.   IPC: A61K39/00 Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with primed dendritic cells recognizing a tumor antigen. The methods may comprise storing, shipping and/or culturing dendritic cells, where the dendritic cells are stored on a hard surface. Lysis protocols are described where the lysis does not result in complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.
13
US10357553B2
Compositions and methods for combination therapy with dengue virus and dendritic cells
Publication/Patent Number: US10357553B2 Publication Date: 2019-07-23 Application Number: 16/172,487 Filing Date: 2018-10-26 Inventor: Lyday bruce w   Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.   IPC: A61K35/76 Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
14
US2019298764A1
COMBINATION IMMUNOTHERAPIES FOR TREATMENT OF CANCER
Publication/Patent Number: US2019298764A1 Publication Date: 2019-10-03 Application Number: 16/413,444 Filing Date: 2019-05-15 Inventor: Lyday bruce w   Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.   IPC: A61K35/15 Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with an immune checkpoint modulatory agent and a strain of an Arbovirus or a strain of an Alphavirus. Also provided herein are also methods for combination therapy comprising administration of an immune checkpoint modulatory agent, tumor antigen primed dendritic cells and an Alphavirus or an Arbovirus.
15
US10293038B2
Compositions and methods for combination therapy with dengue virus and dendritic cells
Publication/Patent Number: US10293038B2 Publication Date: 2019-05-21 Application Number: 16/172,487 Filing Date: 2018-10-26 Inventor: Lyday bruce w   Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.   IPC: A61K35/76 Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
16
US2019046622A1
COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
Publication/Patent Number: US2019046622A1 Publication Date: 2019-02-14 Application Number: 16/172,487 Filing Date: 2018-10-26 Inventor: Lyday bruce w   Assignee: PrimeVax Immuno-Oncology, Inc.   IPC: A61K39/00 Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
17
EP3541417A1
COMBINATION IMMUNOTHERAPIES FOR TREATMENT OF CANCER
Publication/Patent Number: EP3541417A1 Publication Date: 2019-09-25 Application Number: 17871276.6 Filing Date: 2017-11-15 Inventor: Lyday bruce w   Assignee: Primevax Immuno-Oncology, Inc.   IPC: A61K39/12
18
EP3565567A1
COMPOSITIONS AND METHODS FOR THERAPY WITH DENGUE VIRUS
Publication/Patent Number: EP3565567A1 Publication Date: 2019-11-13 Application Number: 18736627.3 Filing Date: 2018-01-04 Inventor: Lyday bruce w   Assignee: Primevax Immuno-Oncology, Inc.   IPC: A61K35/76
19
US2019247479A1
COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
Publication/Patent Number: US2019247479A1 Publication Date: 2019-08-15 Application Number: 16/389,445 Filing Date: 2019-04-19 Inventor: Lyday bruce w   Assignee: PrimeVax Immuno-Oncology, Inc.   IPC: A61K39/00 Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
20
WO2018093907A1
COMBINATION IMMUNOTHERAPIES FOR TREATMENT OF CANCER
Publication/Patent Number: WO2018093907A1 Publication Date: 2018-05-24 Application Number: 2017061810 Filing Date: 2017-11-15 Inventor: Lyday, Bruce W   Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.   IPC: A61P35/04 Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with an immune checkpoint modulatory agent and a strain of an Arbovirus or a strain of an Alphavirus. Also provided herein are also methods for combination therapy comprising administration of an immune checkpoint modulatory agent, tumor antigen primed dendritic cells and an Alphavirus or an Arbovirus.
Total 3 pages